Drugs in the making.com
Dr.Shruti Bhat, Leader Pharmaceutical R&D and Expert in hiTech formulation development for over 35 different therapeutic class of drugs moeities, brings to you some highlights from current pharma and clinical research news, views and data.
Presented below are updates in Pharmaceutical and clinical research-
Teva Announces Positive Results from a Study Assessing a New Formulation of Copaxone(R). Significantly less pain and fewer injection site reactions were reported by patients receiving the new lower volume injection.
Teva Pharmaceutical Industries Ltd. announced positive results from a study assessing a new lower-volume injection of Copaxone(R) (glatiramer acetate) containing the currently approved dose in half the injection volume. The SONG study ('Study of New Glatiramer Acetate Formulation') explored the safety and tolerability of...
Starpharma Plans Effectiveness Studies On Herpes-Killing Gel For Women.
Bloomberg News reported, "The world's first herpes-killing vaginal gel may go on sale within two years, said its developer Starpharma Holdings Ltd., which plans to start patient studies on its effectiveness." Starpharma CEO Jackie Fairley said ...
Bevacizumab May Improve Some Outcomes In Advanced Gastric Cancers.
MedPage Today reported that "bevacizumab (Avastin) may improve some outcomes in advanced gastric cancers, but it did not benefit overall survival, according to ...
Erlotinib May Prolong Survival In Older Women With Advanced Non-Small Cell Lung Cancer.
MedPage Today reported that "the targeted agent erlotinib (Tarceva) prolonged survival by 26% in older women with advanced non-small cell lung cancer, but did not benefit men with the disease," according to research presented ...
Mapatumumab Fails In Midstage Study.
"Human Genome Sciences's potential cancer drug mapatumumab failed in a midstage study. The company found "no difference in disease response ...
Rosiglitazone, Metformin Low-Dose Combination May Reduce Progression To Type 2 Diabetes.
The Los Angeles Times reported, "A combination of low doses of the diabetes drugs Avandia [rosiglitazone] and metformin can reduce the progression to type 2 diabetes by two-thirds in people who are at high risk of developing the disease," according to a study published online in The Lancet. In fact, "the benefit is greater than with either of the drugs used alone, and ...
More at http://www.pharm-education.com/2010/06/rosiglitazone-metformin-low-dose.html
Http://www.drshrutibhat.comExpert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10
Shruti has initiated a new blog Http://www.PharmaceuticalCareerDevelopment.blogspot.com which contains articles on motivation, career counselling and coaching, job search strategies, personal branding etc. especially for pharma professionals.
Do you have questions for the author?
Dr. Shruti Bhat
Pharmaceutical Manufacturing, Continuous Improvement and Business Transformation Consultant
New Release !
The information posted here, not limited to blogs, website, podcasts, videos, eBooks, whitepapers and other 'free' resources including downloaded items are Copyright protected, 'for review' purpose only. Not to be copied, distributed or used without prior written authorization by Dr. Shruti U. Bhat. Any instance(s) found to the contrary would be construed as copyright violation, illegal, plagiarism and/or could be subject to legal proceedings.
For additional details, refer our Terms & Conditions for site usage.
Kaizen book at # 4 on Amazon Best Sellers List!